Download presentation
Presentation is loading. Please wait.
Published byAlannah Crawford Modified over 6 years ago
1
From: Suppression of Laser-Induced Choroidal Neovascularization by a CCR3 Antagonist
Invest. Ophthalmol. Vis. Sci ;54(2): doi: /iovs Figure Legend: VEGF protein levels in the RPE/choroid. (A) The VEGF levels in the RPE/choroid are significantly increased at 3 days after the laser injury in control DMSO– and CCR3 antagonist–injected eyes. Data are means ± SEM (n = 5). *P < 0.05 versus day 0. Intravitreous injection of the CCR3 antagonist at 10.0 μg does not suppress VEGF expression. NS, not significant. (B, C) Western blot analyses showing induction of two isoforms of VEGF protein. The VEGF level in the RPE/choroid is upregulated at 1 day after the laser photocoagulation, and reaches a peak at 3 days after the laser injury. In DMSO-injected eyes, the VEGF164 isoform shows a very strong response, whereas VEGF120 shows only a marginal response. In contrast, in YM –treated eyes, the VEGF120 isoform shows a very strong response, whereas VEGF164 shows only a marginal response at 3 days after laser photocoagulation. The membranes were scanned using a flatbed scanner and the band intensities analyzed using ImageJ software. The expression levels are calculated as percentages of the VEGF expression in the day 0 control. (D, E) Real-time RT-PCR analysis showing CCR3 antagonist treatment suppressed VEGF164 upregulation and induced VEGF120 expression. Vegfa120 mRNA expression in RPE/choroid of CCR3 antagonist–treated eyes was significantly upregulated and Vegfa164 mRNA expression was significantly suppressed compared with DMSO-injected eyes at 24 hours after the laser injury. Gene expression measured by real time RT-PCR was normalized to GAPDH mRNA levels and to baseline levels (n = 6). *P < 0.05 compared to control (day 0). (F) Real-time RT-PCR analysis showing CCR3 antagonist resulted in a reversal of the relative ratio of VEGF120 to VEGF164 mRNA, with VEGF120 upregulation at 24 hours after the laser injury (*P = , compared to DMSO-treated eyes). Date of download: 10/20/2017 The Association for Research in Vision and Ophthalmology Copyright © All rights reserved.
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.